(CercleFinance.com) – Sandoz, the biosimilar drugs subsidiary of Novartis, announced on Friday the launch of generic versions of two famous anti-diabetics from Merck on the Canadian market.
PrSandoz Sitagliptin, a generic version of Januvia from Merck, and PrSandoz Sitagliptin-Metformin, a generic version of Janumet tablets are indicated as monotherapy as adjunctive therapy to improve glycemic control in patients adults with type 2 diabetes.
They are also used to help reduce long-term complications associated with the disease and maintain quality of life over time.
In complementary combinations, they are indicated as an adjunct to diet and physical activity for the regulation of blood sugar in adult patients with type 2 diabetes.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
